LIKMEZ is an FDA-approved, ready-to-use oral suspension containing metronidazole at a labeled concentration of 500 mg per 5 mL. Unlike standard metronidazole tablets, it is a liquid oral medicine with its own instructions, product codes and dispensing considerations. The distinguishing commercial question is not whether metronidazole works in general, but whether an oral suspension is the dosage form the prescriber intends and whether a pharmacy can correctly supply and label that specific medicine.
This brand is particularly relevant when a patient cannot use solid oral dosage forms and a clinician has determined that a liquid is appropriate. However, a liquid formulation should never be inferred from a tablet prescription or casually replaced with a compounded mixture. LIKMEZ is an approved product, while pharmacy-compounded metronidazole liquids do not automatically hold the same approval or equivalence status. Our oral metronidazole suspension overview explains the form-level distinction.
The LIKMEZ guide covers brand identity, exact concentration, a pharmacist's verification workflow and the regulatory difference between approved and compounded products. It does not estimate in-stock quantities or provide self-selected regimens. For broader comparisons of oral drug formats, consult LIKMEZ versus metronidazole tablets before discussing a prescription change with a clinician.
A ready-to-use suspension is an engineered dosage form, not merely the contents of a crushed tablet stirred into liquid. LIKMEZ labeling identifies metronidazole 500 mg in every 5 mL; this equates to a concentration of 100 mg/mL. The concentration belongs to the named product, and a prescription must specify a suitable measured amount. A patient should not treat milliliters as interchangeable with milligrams or compare two bottles without checking their labels.
The U.S. label also makes clear that LIKMEZ is for oral use and contains a prescription antimicrobial. It is not a vaginal gel, rosacea cream or over-the-counter liquid. An FDA-approved listing verifies a defined product's regulatory identity, but the listed product may or may not be obtainable from a particular pharmacy at a given moment.
| Product being compared | Route or preparation | What must match the order |
|---|---|---|
| LIKMEZ | Approved, ready-to-use oral suspension; 500 mg/5 mL | Brand or equivalent product, liquid concentration, measured amount, quantity |
| Generic oral metronidazole tablets | Oral solid tablets; strengths differ | Tablet strength and directions; no assumed liquid equivalence |
| Flagyl 375 capsule | Distinct oral capsule formulation | Capsule dosage form and prescribed strength |
| Individually compounded oral liquid | Patient-specific preparation; not FDA-approved as a drug | Clinical need, compounding prescription and pharmacy preparation details |
LIKMEZ was developed as the first FDA-approved ready-to-use metronidazole oral suspension in the U.S. This status makes the product's reviewed formulation, concentration and labeling publicly identifiable. It does not mean LIKMEZ is automatically preferable for every condition, age group or patient; those judgments remain clinical. The label's current indications and warnings, not broad marketing language about liquids, should govern evaluation.
Prior to an approved ready-to-use suspension, some patients requiring a metronidazole liquid received pharmacy-compounded preparations. That history explains a practical need for the brand, but compounded products are not FDA-approved and should not be called its generic equivalents without an applicable FDA approval. If a dispenser proposes a non-branded liquid, ask exactly what approval or preparation category applies.
The distinction between 500 mg and 5 mL is essential. The first is an amount of active drug, while the second is a volume of the labeled suspension. The prescriber chooses the clinical regimen; the pharmacist translates the valid order into instructions using the labeled concentration and an appropriate measuring device. The appearance of a bottle or an advertised volume cannot tell a patient what amount to take.
Ask whether a supplied measuring device suits the prescribed volume and whether the container carries the exact product name, strength per unit volume, directions, storage requirements and expiration information. Do not use kitchen spoons or substitute an unverified liquid concentration. Specific questions about handling should be resolved using the dispensed product's directions and pharmacist counseling.
The LIKMEZ labeling identifies uses including trichomoniasis, amebiasis and certain anaerobic bacterial infections, with circumstances and restrictions specified in the prescribing information. An oral suspension may make drug administration feasible for some patients, but the liquid does not create a new indication or eliminate the need for diagnosis. It remains a systemic antimicrobial with important contraindications, warnings and interaction considerations.
Systemic metronidazole should not be selected because it is easier to swallow or has a familiar brand name. The prescriber must decide whether this drug, this formulation and a suitable regimen fit the patient. For readers who first need to identify the whole oral family, the oral metronidazole guide separates capsules, standard tablets, extended-release products and suspension.
FDA distinguishes a manufactured, approved drug from a compounded drug prepared to meet an individual patient's need. Compounding can be appropriate in particular clinical circumstances, but FDA does not assess each compounded product for safety, effectiveness and quality before marketing. A listing labeled 'metronidazole suspension' therefore needs closer examination: it may describe LIKMEZ, another approved product, or a compounded preparation with different properties.
If the prescription calls for LIKMEZ, ask the dispensing pharmacist whether the exact named product is being supplied. If they propose a compounded alternative, the clinician should assess whether that is permitted and appropriate, especially when an approved formulation might already meet the need. Do not infer stability, flavor, concentration or substitution equivalence from a generic-sounding online description.
A lawful purchase begins with a qualified prescriber and a written or electronic prescription that identifies the oral suspension clearly. A pharmacist then checks the prescribed concentration, quantity and patient instructions and can confirm if the product is available through its suppliers. Delays, coverage review or a need to contact the prescriber may arise even if the product has an FDA-approved label.
When comparing pharmacies, request the exact product identity rather than asking for 'liquid Flagyl' or 'metronidazole syrup.' Online pharmacies should require the prescription and provide licensed pharmacist access. The general online pharmacy checks apply, but they do not independently establish that LIKMEZ is in stock.
Being liquid does not make an antibiotic free from systemic risks. LIKMEZ has a boxed warning concerning carcinogenicity findings in rodents, as well as other precautions and interaction information in its label. The potential relevance of medical conditions, allergies, other drugs, pregnancy or breastfeeding must be assessed by the treating clinician. Parents and caregivers should not assume that an approved liquid implies universal pediatric suitability.
Verify that any counseling relates to the actual LIKMEZ suspension instead of a tablet insert or a topical product's directions. If the patient has difficulty swallowing, changes in symptoms or adverse effects, contact the care team. Do not adjust volume or reuse previously prescribed liquid for a new illness.
Liquid medicines introduce practical details that tablet purchases may not have: bottle volume, dosage measure, handling instructions, product stability and expiration information. Packaging and storage should follow the particular manufacturer's label and the pharmacy's dispensing instructions. A pharmacy listing that states only 'metronidazole oral' omits information needed to establish a proper match.
The current product label should govern measuring, shaking, storage and the discard period after the bottle is opened. DailyMed contains different LIKMEZ label records: one older 200 mL presentation specified discarding 10 days after opening, whereas a later label listing 75 mL and 200 mL presentations specifies 60 days after opening. These are not instructions to select a shelf life independently. Ask the dispensing pharmacist which current labeled product was supplied, shake as directed, use a calibrated oral dosing device and follow the expiration or after-opening date supplied for that exact bottle.
A ready-to-use branded liquid may be handled differently by insurance than low-cost generic oral tablets. Plan formularies, prior authorization rules, pharmacy networks and the prescribed bottle quantity can all affect what the patient owes. An online dollar figure without the exact dosage form and benefits information does not answer the real affordability question.
Consult the LIKMEZ cost guide for evergreen pricing factors. Before paying, ask the pharmacy whether the quote refers to LIKMEZ, an approved alternative or a compounded formulation; these should not be combined in one comparison. Current stock and final cost can only be confirmed by the relevant provider and pharmacy.
Confirm that the prescription specifies an oral metronidazole suspension; identify whether LIKMEZ was explicitly intended; verify the concentration of 500 mg per 5 mL; check the prescribed volume and total quantity; and confirm the pharmacist can explain preparation-specific handling. None of these checks substitutes for the clinician's choice of therapy, but they reduce the chance of confusing liquids and tablets.
If any part of the order differs from the actual product, do not calculate a replacement from a different bottle or strength. Ask the pharmacist to contact the prescriber and resolve the mismatch through proper channels. This is particularly important when a seller calls an unapproved compounded liquid 'generic LIKMEZ.'
LIKMEZ is an FDA-approved prescription metronidazole oral suspension supplied as a ready-to-use liquid with its own labeling.
The U.S. labeled concentration is 500 mg of metronidazole per 5 mL, equivalent to 100 mg/mL. A prescriber and pharmacist determine the appropriate measured amount.
No. LIKMEZ is a liquid oral dosage form; tablets are solid products with their own strengths and instructions. They should not be substituted without appropriate professional review.
No. LIKMEZ is an oral suspension, not a vaginal gel or topical skin medicine.
Not merely because it contains metronidazole. Compounded drugs are not FDA-approved generics, and any alternative liquid requires an appropriate prescribing and dispensing decision.
No. LIKMEZ is a prescription medicine and must be dispensed under applicable U.S. requirements.
No. FDA approval and published labeling do not indicate a particular pharmacy’s real-time supplier inventory.
Follow the dispensing pharmacist’s instructions and use an appropriate medication-measuring device for the prescribed liquid volume, rather than a household spoon.
Costs can differ because brand status, liquid formulation, bottle quantity and insurance rules differ from those for generic tablets. Ask for a quote for the exact prescribed product.
A prescriber and pharmacist must evaluate any proposed change. Do not convert liquid volumes into tablet counts independently.